Continuing Education Event – Medication for Addiction Treatment (MAT) – webinar – 3/23/2022
Recovery Centers of America has been approved by NBCC as an Approved Continuing Education Provider, ACEP No. 7002. Programs that do not qualify for NBCC credit are clearly identified. Recovery Centers of America is solely responsible for all aspects of the programs. This course qualifies for 1.5 credit hours.
Medication for Addiction Treatment (MAT) is the use of medications that are used both for Alcohol Use Disorder and Opioid Use Disorder, in combination with counseling and behavioral therapies to provide a patient approach to the treatment of Substance Use Disorders. Medications used in MAT are approved by the Food and Drug Administration (FDA) and MAT programs are clinically driven and tailored to meet each patient’s needs. Certain Specific MAT medications (i.e., buprenorphine, methadone) can also be used for acute detoxification and withdrawal management to complete abstinence from Opioids (i.e., Drug-Free approach). This approach without a long-term plan for sustained abstinence (i.e., counseling, behavioral therapies, without MAT medications) can be fraught with a risk of overdose and death with return use of drugs in an era of fentanyl use.
Research shows that a combination of medication and therapy can successfully treat these disorders, and for some people struggling with addiction, MAT can help sustain recovery. MAT is also used to prevent or reduce opioid overdose. MAT can help sustain Harm reduction which is an effective approach to addressing the public health epidemic involving substance use as well as infectious disease and other harms associated with drug use.
– Understanding the difference between Drug-Free and MAT Medication Assisted Treatment and the Vulnerability of an Opioid Overdose.
– Understanding Medication for Addiction Treatment for Alcohol Use Disorder and Opioid Use Disorder.
– Understanding Risk Mitigation in the context of Medication Assisted Treatment for Opioid Use Disorder.
– Understanding the Vulnerability of an Opioid overdose with Vivitrol, at the end of a dosing interval, after missing a scheduled dose, or after discontinuing treatment.
Dr. Joseph Ranieri D.O. earned his BS in Pharmacy at Temple University School of Pharmacy in 1981 and His Doctorate Degree in Osteopathic Medicine at the Philadelphia College of Osteopathic Medicine in 1991. He is Board Certified by the American Board of Family Medicine and a Diplomate of the American Board of Preventive Medicine Addiction Certification. He is also a Fellow of the American Academy of Family Practice and the American Society of Addiction Medicine. He has practiced in South Jersey since 1995. Starting in 2007, while practicing Family Medicine, he incorporated Addiction Treatment Modalities for his primary care patients. Dr. Ranieri has lectured extensively to physicians, nurses, counselors and laypeople about the Disease of Addiction throughout New Jersey and Pennsylvania since 2012.
He has continued to volunteer for a Christian Discipleship Recovery House since 2003 as well as being a Drug and Alcohol Monitor for the Professional Assistance Program (formerly PHP) of New Jersey since 1998. Additionally, he is a Clinical Associate Professor, Physician Assistant Program at PCOM.
South Jersey Biz “Who’s Who in Health Care recognized Dr. Ranieri for contributions to Addiction Medicine as well as other receiving recognition from other organizations. Dr. Ranieri is the Past President of the NJ Society of Addiction Medicine. He oversees aspects of the Addiction & Medical Treatment Modalities of patients for Medication Assisted Treatment (MAT) / Medication for Opioid Use Disorder (MOUD) (i.e., Methadone, Buprenorphine, Extended-release naltrexone, Extended-release buprenorphine) and Extended-release naltrexone, oral naltrexone and acamprosate for Alcohol Use Disorder at the Recovery Centers of America MAT program as well as his private OBOT (Office Based Opioid Treatment). He also recognizes the importance of incorporating bio-psychosocial modalities into Addiction Treatment. Dr. Ranieri provides medical expertise, education, and insight about the Chronic Disease of Addiction. Dr. Ranieri’s vision is to educate and empower Physician’s, Mid-Level Provider’s (APN / PA’s), Nurse’s and Clinical Therapist’s to minister to the Physical, Mental, Spiritual and Health Care needs of those suffering with the Disease of Addiction from Alcoholism and Substance Use Disorder. Dr Ranieri believes in incorporating the following modalities to Treat the whole person from a Medical, Bio-Psychosocial, Behavioral, Spiritual, Osteopathic, and Holistic Philosophy.
Dr. Ranieri is currently the Medical Director for RCA Outpatient OTP Delaware County Healthcare Clinic in Lansdowne, Pa and Woodbridge Healthcare Clinic in Iselin, NJ.
Disclosure: Dr. Ranieri is a Paid consultant for Alkermes the manufacturer of Extended-release Naltrexone (Vivitrol).